186 related articles for article (PubMed ID: 21606663)
1. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Krishnan S; Schouten JT; Jacobson DL; Benson CA; Collier AC; Koletar SL; Santana J; Sattler FR; Mitsuyasu R;
Oncology; 2011; 80(1-2):42-9. PubMed ID: 21606663
[TBL] [Abstract][Full Text] [Related]
2. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.
Chao C; Leyden WA; Xu L; Horberg MA; Klein D; Towner WJ; Quesenberry CP; Abrams DI; Silverberg MJ
AIDS; 2012 Nov; 26(17):2223-31. PubMed ID: 22951631
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
[TBL] [Abstract][Full Text] [Related]
4. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Yanik EL; Napravnik S; Cole SR; Achenbach CJ; Gopal S; Dittmer DP; Olshan AF; Kitahata MM; Mugavero MJ; Saag M; Moore RD; Mathews WC; Hunt P; Eron JJ
AIDS; 2014 Apr; 28(7):979-87. PubMed ID: 24681415
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; de Wit S; D Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):568-77. PubMed ID: 25763785
[TBL] [Abstract][Full Text] [Related]
6. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.
Worm SW; Bower M; Reiss P; Bonnet F; Law M; Fätkenheuer G; d'Arminio Monforte A; Abrams DI; Grulich A; Fontas E; Kirk O; Furrer H; De Wit S; Phillips A; Lundgren JD; Sabin CA;
BMC Infect Dis; 2013 Oct; 13():471. PubMed ID: 24106926
[TBL] [Abstract][Full Text] [Related]
7. A case-control study of non-AIDS-defining cancers in a prospective cohort of HIV-infected patients.
Rodríguez Arrondo F; von Wichmann MÁ; Camino X; Goenaga MÁ; Ibarguren M; Azcune H; Bustinduy MJ; Ferrero O; Muñoz J; Ibarra S; Aguirrebengoa K; Goicoetxea J; Bereciartua E; Montejo M; García MA; Martínez E; Portu J; Metola L; Silvariño R; Sarasqueta C; Arrizabalaga J; Iribarren JA;
Med Clin (Barc); 2018 Apr; 150(8):291-296. PubMed ID: 28528797
[TBL] [Abstract][Full Text] [Related]
8. The Association of HIV Control and Immunosuppression With Risk of Non-AIDS-Defining Cancer Risk Among Patients on Antiretroviral Therapy.
Dickey BL; Yanik EL; Thompson Z; Burkholder G; Kitahata MM; Moore RD; Jacobson J; Mathews WC; Christopoulos KA; Fleming J; Napravnik S; Achenbach C; Coghill AE
J Acquir Immune Defic Syndr; 2024 Mar; 95(3):275-282. PubMed ID: 37977197
[TBL] [Abstract][Full Text] [Related]
9. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.
Chammartin F; Lodi S; Logan R; Ryom L; Mocroft A; Kirk O; d'Arminio Monforte A; Reiss P; Phillips A; El-Sadr W; Hatleberg CI; Pradier C; Bonnet F; Law M; De Wit S; Sabin C; Lundgren JD; Bucher HC;
Ann Intern Med; 2021 Jun; 174(6):768-776. PubMed ID: 33721519
[TBL] [Abstract][Full Text] [Related]
10. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
11. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)].
Iribarren JA; Labarga P; Rubio R; Berenguer J; Miró JM; Antela A; González J; Moreno S; Arrizabalaga J; Chamorro L; Clotet B; Gatell JM; López-Aldeguer J; Martínez E; Polo R; Tuset M; Viciana P; Santamaría JM; Kindelán JM; Ribera E; Segura F; ;
Enferm Infecc Microbiol Clin; 2004 Dec; 22(10):564-642. PubMed ID: 15596051
[TBL] [Abstract][Full Text] [Related]
12. HIV infection and the risk of cancers with and without a known infectious cause.
Silverberg MJ; Chao C; Leyden WA; Xu L; Tang B; Horberg MA; Klein D; Quesenberry CP; Towner WJ; Abrams DI
AIDS; 2009 Nov; 23(17):2337-45. PubMed ID: 19741479
[TBL] [Abstract][Full Text] [Related]
13. Impact of antiretroviral treatment on height evolution of HIV infected children.
Traisathit P; Urien S; Le Coeur S; Srirojana S; Akarathum N; Kanjanavanit S; Ngampiyaskul C; Krikajornkitti S; Ngo-Giang-Huong N; Lallemant M; Jourdain G
BMC Pediatr; 2019 Aug; 19(1):287. PubMed ID: 31421667
[TBL] [Abstract][Full Text] [Related]
14. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012.
Park LS; Tate JP; Sigel K; Rimland D; Crothers K; Gibert C; Rodriguez-Barradas MC; Goetz MB; Bedimo RJ; Brown ST; Justice AC; Dubrow R
AIDS; 2016 Jul; 30(11):1795-806. PubMed ID: 27064994
[TBL] [Abstract][Full Text] [Related]
15. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy.
Koethe JR; Jenkins CA; Petucci C; Culver J; Shepherd BE; Sterling TR
Medicine (Baltimore); 2016 May; 95(19):e3634. PubMed ID: 27175676
[TBL] [Abstract][Full Text] [Related]
16. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
[TBL] [Abstract][Full Text] [Related]
17. Malignancy Trends in HIV-Infected Patients Over the Past 10 Years in a Single-Center Retrospective Observational Study in the United States.
Rihana N; Nanjappa S; Sullivan C; Velez AP; Tienchai N; Greene JN
Cancer Control; 2018; 25(1):1073274818797955. PubMed ID: 30185062
[TBL] [Abstract][Full Text] [Related]
18. Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.
Boettiger DC; Sudjaritruk T; Nallusamy R; Lumbiganon P; Rungmaitree S; Hansudewechakul R; Kumarasamy N; Bunupuradah T; Saphonn V; Truong KH; Yusoff NKN; Do VC; Nguyen LV; Razali KAM; Fong SM; Kurniati N; Kariminia A
J Adolesc Health; 2016 Apr; 58(4):451-459. PubMed ID: 26803201
[TBL] [Abstract][Full Text] [Related]
19. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
20. Risk of cancers during interrupted antiretroviral therapy in the SMART study.
Silverberg MJ; Neuhaus J; Bower M; Gey D; Hatzakis A; Henry K; Hidalgo J; Lourtau L; Neaton JD; Tambussi G; Abrams DI
AIDS; 2007 Sep; 21(14):1957-63. PubMed ID: 17721103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
